Today: 7 February 2026
Subscribe
Browse Category

Investment Analysis News 12 January 2026 - 13 January 2026

JPMorgan Chase stock falls after Apple Card reserve hits profit as rate-cap risk hangs over banks

JPMorgan Chase stock falls after Apple Card reserve hits profit as rate-cap risk hangs over banks

New York, Jan 13, 2026, 11:02 ET — Regular session JPMorgan Chase & Co shares were down 2.5% at $316.32 in late morning trade on Tuesday, after swinging between $331.00 and $313.96 earlier in the session. The bank reported fourth-quarter net income of $13.0 billion, or $4.63 a share, after setting aside $2.2 billion tied to its forward purchase of the Apple credit card portfolio. “The Firm concluded the year with a strong fourth quarter,” CEO Jamie Dimon said in the release. (SEC) The print lands as Washington re-opens a fight over what credit should cost. Analysts at TD Cowen
13 January 2026
····
Abercrombie & Fitch stock: what comes next after the 18% plunge on outlook update

Abercrombie & Fitch stock: what comes next after the 18% plunge on outlook update

NEW YORK, Jan 13, 2026, 04:45 EST — Premarket Abercrombie & Fitch (ANF.N) held steady near $102.78 in premarket Tuesday, following a sharp 17.7% drop the previous day. The stock closed Monday at $102.78, with roughly 6.6 million shares exchanged, after the company trimmed some of its guidance. (Yahoo Finance) This shift matters today because the update didn’t signal falling demand — it flagged tighter economics. A small cut to sales growth, weaker margin forecasts, and ramped-up spending can easily unsettle a retail stock riding high on expectations. The news came as retailers gathered with investors at the ICR Conference,
13 January 2026
·····
BAE Systems stock dips after a record close — here’s what traders are watching next

BAE Systems stock dips after a record close — here’s what traders are watching next

London, January 13, 2026, 08:36 GMT — Regular session BAE Systems (BAES.L) shares fell 1.4% to 2,064 pence by mid-morning in London on Tuesday, easing after a sharp early-January rally. The stock trades at about 30 times estimated 2025 earnings, MarketScreener data showed. (MarketScreener) That leaves BAE just below Monday’s intraday peak of 2,119 pence, after it closed at 2,093 pence. Even with Tuesday’s dip, the shares are up about 18% since Jan. 2, when they ended at 1,754 pence, according to Investing.com price data. (Investing.com) Investors had little fresh company news to trade on. BAE is due to publish
13 January 2026
····
BP PLC stock watch: cost-cut pledge, oil jump and buyback keep shares in play

BP PLC stock watch: cost-cut pledge, oil jump and buyback keep shares in play

LONDON, Jan 13, 2026, 08:28 GMT — Regular session BP shares (BP.L) inched up roughly 0.3% to 427.7 pence during early trade in London on Tuesday, finding footing following recent management comments on costs and strategy. (Investing.com) The stock has returned to focus as BP undergoes a leadership transition, with investors eager to understand what shifts, if any, lie ahead. Meanwhile, oil prices are moving independently, often overshadowing company-specific updates on any given day. Interim CEO Carol Howle told staff at a recent town hall that the company’s strategy and cost-cutting focus remain unchanged, according to two insiders. Howle stepped
13 January 2026
·····
Confluent scraps earnings call ahead of IBM takeover — what it means for CFLT stock

Confluent scraps earnings call ahead of IBM takeover — what it means for CFLT stock

NEW YORK, Jan 13, 2026, 02:45 EST Confluent (CFLT.O) said on Monday it will report fourth-quarter and full-year 2025 results on Feb. 11, but it will not hold an earnings conference call or provide a financial outlook because of its pending sale to IBM (IBM.N). https://www.businesswire.com/news/home/20260112152645/en/Confluent-to-Announce-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-on-February-11-2026 That matters now because earnings calls are usually where management answers the only question deal traders keep asking: is anything slowing down. With no call, the stock loses one of its few near-term pressure points. The absence of guidance also keeps the focus on timing and odds, not the quarter itself. For a cash
13 January 2026
·····
Oklo stock slips as insiders sell shares and traders reassess Meta nuclear deal

Oklo stock slips as insiders sell shares and traders reassess Meta nuclear deal

New York, Jan 12, 2026, 20:56 EST — Market closed. Oklo Inc (OKLO) shares fell 2.7% on Monday to close at $102.50, paring a run that has taken the stock up about 43% since the end of 2025. The pullback followed Friday’s jump, when the stock swung as high as $115.72 after news tied it more closely to Meta Platforms’ push to lock in nuclear power for data centers. (Investing.com) The move matters because Oklo has become one of the market’s higher-beta ways to trade the “AI power demand” theme. Meta said on Friday it struck 20-year agreements to buy
13 January 2026
·····
GE Aerospace stock heads into earnings week as Airbus flags engine delays and brokers tweak targets

GE Aerospace stock heads into earnings week as Airbus flags engine delays and brokers tweak targets

NEW YORK, Jan 12, 2026, 8:14 PM EST — Market closed GE Aerospace (GE) shares closed Monday at $324.17, up 0.8%, following Wolfe Research’s update. The firm lifted its price target to $360 from $340 and kept its Outperform rating. (MarketScreener) U.S. markets were closed Monday, shifting focus as stocks head into Tuesday toward a familiar issue: can jetmakers secure enough engines and parts to maintain their assembly lines? GE’s earnings report next week has traders watching supply chain updates closely, keeping aerospace stocks in the spotlight. Airbus voiced worries Monday over engine deliveries from Pratt & Whitney, owned by
13 January 2026
·······
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

New York, Jan 12, 2026, 20:02 EST — Market closed Alnylam Pharmaceuticals’ shares fell sharply on Monday after the drugmaker’s preliminary fourth-quarter sales for its flagship heart drug Amvuttra came in below Wall Street expectations. The decline hit as investors digested the company’s new five-year strategy and 2026 revenue outlook, rolled out around the J.P. Morgan Healthcare Conference in San Francisco. Why it matters now: early-January “preannouncements” can reset the bar ahead of earnings season, and Amvuttra has become Alnylam’s core growth driver. A small miss on that product can outweigh upbeat long-range targets, at least for a session or
13 January 2026
·····
Exxon stock slips after Trump hints at Venezuela block — what to watch before Tuesday

Exxon stock slips after Trump hints at Venezuela block — what to watch before Tuesday

New York, Jan 12, 2026, 18:53 EST — After-hours Exxon Mobil shares slipped in after-hours trading Monday following President Donald Trump’s comment that he might block the oil giant from Venezuela’s reopening—a rare public rebuke aimed at the company’s CEO. This episode is crucial as Washington moves fast to redirect Venezuela’s oil shipments following last week’s power shift in Caracas. Investors are scrambling to figure out which producers could tap into those barrels—and on what terms. Exxon investors now face an extra political risk on top of an already volatile oil market. Moves benefiting Venezuela’s competitors might not shift the
13 January 2026
····
Micron stock holds near a fresh high as suppliers lift chip testing fees; what comes next

Micron stock holds near a fresh high as suppliers lift chip testing fees; what comes next

New York, Jan 12, 2026, 16:47 ET — After-hours Micron Technology shares ended slightly higher on Monday and were little changed in after-hours trading after a report said memory-chip testing and packaging vendors have raised prices by as much as 30%, adding another pressure point in a tight supply chain. The stock closed at $345.87, up 0.2%, after touching a session high that matched its 52-week peak. (Investing.com) The fee hikes matter because outsourced assembly and test, known as OSAT, is the packaging and checking step that comes after chips are made — and it can turn into a bottleneck
12 January 2026
·····
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

New York, Jan 12, 2026, 16:34 (EST) — After-hours Alnylam Pharmaceuticals shares dropped in late Monday trading after the RNA interference drugmaker unveiled a new five-year plan and provided early 2026 sales guidance, along with preliminary figures for 2025. The stock slipped roughly 6.7% to $370.91. The company unveiled its “Alnylam 2030” initiative, aiming for “leadership in ATTR amyloidosis” and “sustained, profitable growth.” It’s targeting total revenue compound annual growth above 25% through 2030, along with a non-GAAP operating margin near 30%. For 2026, combined net product revenue is expected between $4.9 billion and $5.3 billion, spanning AMVUTTRA, ONPATTRO, GIVLAARI,
12 January 2026
·····
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

New York, January 12, 2026, 15:41 ET — Regular session Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading. The message is crucial as Arcutis hits a stage where investors demand more than just rapid script growth — they want evidence it can scale without another cash drain. One marketed franchise can sustain a company, until it can’t. It also
12 January 2026
·····
1 … 53 54 55 56 57 … 282

Stock Market Today

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

7 February 2026
BP shares closed up 1.9% at 478 pence Friday, just below a 52-week high, as the company continued buybacks ahead of next week’s results. BP repurchased 2.789 million shares on February 6. Oil prices firmed on geopolitical risk, with Brent at $68.05 a barrel, but sector outlook remains uncertain. Investors await BP’s earnings and dividend decision due Tuesday.
Go toTop